hypertrophic%20cardiomyopathy
HYPERTROPHIC CARDIOMYOPATHY

Hypertrophic cardiomyopathy is a genetically determined cardiac disorder characterized by hypertrophy, often of the left ventricle (LV), with nondilated ventricular chambers and no other cardiac or systemic disease (eg aortic stenosis, thyroid disease or hypertension) capable of producing the extent of hypertrophy manifested by the patient.

Symptoms can range from patients being asymptomatic to mildly or significantly symptomatic with pre-syncopal or syncopal episodes, palpitations, chest pain, decreased exercise tolerance, symptoms of pulmonary congestion (eg fatigue, dyspnea, orthopnea and paroxysmal nocturnal dyspnea) and symptoms of end-stage heart failure.

Approach to treatment is based on clinical experience and observational data as large randomized trials regarding medical therapy in hypertrophic cardiomyopathy are lacking.

An empiric therapy is often necessary to identify the best possible drug for the patient, starting at a low dose and titrating until clinical improvement or occurrence of side effects.

Treat comorbidities such as hypertension, diabetes, obesity and hyperlipidemia according to existing guidelines due to the significant influence of concomitant coronary artery disease on the survival of patients with hypertrophic cardiomyopathy.

 

Hypertrophic%20cardiomyopathy Signs and Symptoms

Definition

  • A genetically determined cardiac disorder characterized by hypertrophy, often of the left ventricle (LV), with nondilated ventricular chambers and no other cardiac or systemic disease (eg aortic stenosis, thyroid disease or hypertension) capable of producing the extent of hypertrophy manifested by the patient
    • Maximal LV wall thickness of ≥15 mm in adults or ≥2 standard deviations above the mean for age, sex or body size in children
    • Results from mutations in one of the cardiac sarcomere protein genes that encode the parts of the apparatus for contraction: Actin, tropomyosin alpha-1 chain, myosin binding protein C, troponin I, troponin T, beta myosin heavy chain, essential and regulatory light chains

Signs and Symptoms

  • Symptoms can range from patients being asymptomatic to mildly or significantly symptomatic with pre-syncopal or syncopal episodes, palpitations, chest pain, decreased exercise tolerance, symptoms of pulmonary congestion (eg fatigue, dyspnea, orthopnea and paroxysmal nocturnal dyspnea) and symptoms of end-stage heart failure
  • Life expectancy is normal or near-normal in most patients with hypertrophic cardiomyopathy (HCM) though without possibility of remission; mortality is often due to embolic stroke, heart failure with sudden cardiac death

Epidemiology

  • The most common form of genetic cardiovascular disorder occurring in 1 of 200 individuals regardless of gender or race
    • Presents in all age groups
    • An autosomal dominant inherited disorder, affected heterozygous individuals beget children with a 50% risk (equal risk for both males and females) of having the gene mutation
    • Phenotype is abnormal, frequently focal, hypertrophy that leads to atrial and ventricular arrhythmia, diastolic dysfunction, mitral regurgitation, LV outflow tract obstruction (LVOTO), pulmonary hypertension, myocardial ischemia, coronary insufficiency and congestive heart failure
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
Audrey Abella, 16 Sep 2020
The final results of EVAPORATE* reinforce the plaque-regressing potential of icosapent ethyl (IPE) in patients on statins for elevated triglycerides.
01 Feb 2020
High-intensity statin therapy appears to be seeing increased use in patients with acute coronary syndrome and leads to better lipid control, according to a recent Thailand study.